Another FDA checkpoint
Merus just got another notch on zenocutuzumab’s belt: the FDA has received the company’s supplemental BLA, or sBLA, for the bispecific antibody. In plain English, that means the drug is back in the agency’s inbox for a new review, which is how biopharma companies try to expand what a therapy can be used for.
Why this matters
Zenocutuzumab already picked up accelerated approval in December 2024 for adults with advanced unresectable or metastatic NRG1 fusion-positive non-small cell lung cancer or pancreatic ductal adenocarcinoma who had progressed on or after systemic therapy. So this isn’t a moonshot from zero — it’s more like trying to turn an approved niche product into a broader commercial story.
The investor angle
For shareholders, the key question is whether the FDA eventually says yes, because that can mean:
- a bigger label
- a larger addressable market
- more confidence that the drug can become a real revenue engine instead of a science fair trophy
The flip side? Regulatory reviews can drag, and the market usually hates waiting around with its thumb hovering over the refresh button.
Big picture
This is the kind of biotech news that doesn’t always move the stock in a straight line, but it does keep the catalyst machine humming. If zenocutuzumab keeps collecting approvals like Pokemon cards, Merus gets a much better shot at turning promise into sales.